Sumitomo Pharma Co Ltd
TSE:4506
Sumitomo Pharma Co Ltd
Cash & Cash Equivalents
Sumitomo Pharma Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sumitomo Pharma Co Ltd
TSE:4506
|
Cash & Cash Equivalents
¥29B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash & Cash Equivalents
¥457.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash & Cash Equivalents
¥647.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash & Cash Equivalents
¥411.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash & Cash Equivalents
¥462.9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
30%
|
CAGR 10-Years
15%
|
|
Astellas Pharma Inc
TSE:4503
|
Cash & Cash Equivalents
¥335.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
See Also
What is Sumitomo Pharma Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
29B
JPY
Based on the financial report for Mar 31, 2024, Sumitomo Pharma Co Ltd's Cash & Cash Equivalents amounts to 29B JPY.
What is Sumitomo Pharma Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%
Over the last year, the Cash & Cash Equivalents growth was -80%. The average annual Cash & Cash Equivalents growth rates for Sumitomo Pharma Co Ltd have been -47% over the past three years , -27% over the past five years , and 2% over the past ten years .